RT Journal Article
T1 Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation
A1 Araque Arroyo, Patricia
A1 Ubago Perez, Ruth
A1 Fernandez Feijoo, Maria Amalia
A1 Calleja Hernandez, Miguel Angel
K1 Anciano
K1 Antineoplásicos
K1 Análisis Costo-Beneficio
K1 Epirrubicina
K1 Extravasación de Materiales Terapéuticos y Diagnósticos
K1 Humanos
K1 Masculino
K1 Razoxano
K1 Resultado del Tratamiento
K1 Anthracycline
K1 Chemotherapy
K1 cost
K1 Desraxozane
K1 extravasation
AB A 75-year-old man diagnosed with lower esophageal adenocarcinoma suffered from epirubicin extravasation during the second cycle of neoadjuvant chemotherapy with epirubicin and oxaliplatin. A full recovery was achieved after treatment with dexrazoxane (Cardioxane® ). This is the first time in our hospital that extravasation of an anthracycline has been treated with dexrazoxane. We used Cardioxane® , approved for the prevention of anthracycline-induced cardiotoxicity, while Savene® is indicated for the treatment of anthracycline extravasation. The treatment was effective, and the selection of Cardioxane® (seven-fold cheaper than Savene® ) yielded a cost saving. Consequently, Cardioxane® has been included in our guidelines for anthracycline extravasation.
PB Medknow Publications
SN 0973-1482
YR 2011
FD 2011-02-24
LK http://hdl.handle.net/10668/554
UL http://hdl.handle.net/10668/554
LA en
NO Arroyo PA, Perez RU, Feijoo MA, Hernandez MA. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation. J Can Res Ther 2010;6:573-4
NO Case Reports; Journal Article;
DS RISalud
RD Apr 19, 2025